Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Daiichi Sankyo
AstraZeneca
Queensland Health
Express Scripts
Boehringer Ingelheim
Chinese Patent Office
Cipla

Generated: September 21, 2018

DrugPatentWatch Database Preview

DESVENLAFAXINE SUCCINATE Drug Profile

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

When do Desvenlafaxine Succinate patents expire, and what generic alternatives are available?

Desvenlafaxine Succinate is a drug marketed by Actavis Labs Fl, Alembic Pharms Ltd, Casi Pharms Inc, Lupin Ltd, Mylan Pharms Inc, West-ward Pharms Int, and Zydus Pharms Usa Inc. and is included in eight NDAs.

The generic ingredient in DESVENLAFAXINE SUCCINATE is desvenlafaxine succinate. There are sixteen drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the desvenlafaxine succinate profile page.

US Patents and Regulatory Information for DESVENLAFAXINE SUCCINATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Actavis Labs Fl DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204065-001 Jul 29, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Casi Pharms Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204028-002 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Alembic Pharms Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204003-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204082-002 Aug 28, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Lupin Ltd DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204172-001 Jun 29, 2015 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Zydus Pharms Usa Inc DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204020-002 Oct 11, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
West-ward Pharms Int DESVENLAFAXINE SUCCINATE desvenlafaxine succinate TABLET, EXTENDED RELEASE;ORAL 204083-001 Feb 16, 2016 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

see a sample report or, see our see our flat-rate plans

see a sample report or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Cantor Fitzgerald
QuintilesIMS
Daiichi Sankyo
AstraZeneca
Queensland Health
Express Scripts
Boehringer Ingelheim
Chinese Patent Office
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.